MagForce AG Announces Treatment of Recurrent Glioblastoma Patient with NanoTherm Therapy
"We are pleased that treatment with NanoTherm therapy for brain tumors patients has begun, and especially that treatment costs have been supported by a number of state insurance companies through individual patient agreements. This is a great milestone for both our novel technology and for MagForce as a company," said Dr. Peter Heinrich, CEO of MagForce. "Through our collaborations with experts in both Germany and internationally, we plan to further develop this treatment approach for a variety of solid tumor indications with high medical need."
Most read news
Organizations
Other news from the department research and development
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.